Clinical Trial Update: Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating imatinib mesylate in combination with pembrolizumab for melanoma in Phase 1/2; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imatinib mesylate (Imatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Keio University | Conditions: Melanoma | Phase 1, Phase 2 | Status: UNKNOWN